drugset / Trial / NCT04965389

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

NCT04965389

Phase 1 Completed 17 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the absolute oral bioavailability (amount of drug entering the bloodstream) of spray-dried dispersion (SDD) milvexian capsules in the fed and fasted states, and to bridge the exposures seen using only the oral solution.

Timeline

Start
2021-07-16
Primary completion
2021-08-22
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Milvexian Small molecule Intravenous

Indications

No indication recorded.